In a report released today, Robyn Karnauskas from Truist Financial maintained a Buy rating on Progyny (PGNY – Research Report), with a price target of $38.67. The company’s shares closed last Friday at $38.67.
Karnauskas covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Regeneron. According to TipRanks, Karnauskas has an average return of 8.0% and a 50.11% success rate on recommended stocks.
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $43.67.
See Insiders’ Hot Stocks on TipRanks >>
PGNY market cap is currently $3.71B and has a P/E ratio of 74.78.
Based on the recent corporate insider activity of 91 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PGNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progyny (PGNY) Company Description:
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Read More on PGNY:
